drugset / Trial / NCT02281786
A Study of RO6926496 in Healthy Volunteers
RandomizedParallel-groupDouble-blind
Summary
This is a single center, randomized, investigator/subject blind, single ascending dose, placebo-controlled, parallel study that will evaluate the safety, tolerability and pharmacokinetics of RO6926496 in healthy male participants. The dose escalation is adaptive in nature. It is planned to enroll 48 subjects in 6 cohorts. The anticipated total duration of the study is 16 weeks.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO6926496 | Unknown | — | Intravenous |
Indications
No indication recorded.